AtriCure, Inc. (ATRC)
Nasdaq · Healthcare · Medical Instruments & Supplies
$56.37+2.23%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.9B
- P/E (trailing)
- 268.4
- Forward P/E
- 129.9
- 52-week range
- $25.36 – $61.70
- 52-week change
- +61.61%
- EPS (trailing)
- $0.21
- Analyst rating
- 1.9 Buy
- Next earnings
- Oct 27, 2026
Fiscal year to Dec 2025
- Revenue
- $535M (+14.88%)
- Net income
- −$11.4M
- Operating margin
- −1.8%
- Diluted EPS
- −$0.24
- Free cash flow
- $48.3M
From the company’s annual report on SEC EDGAR.
About AtriCure, Inc.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
Headquarters: Mason, United States · 1,350 employees · atricure.com